Polypragmasy and the basics of personalized rational pharmacotherapy selection in older patients with obesity and type 2 diabetes mellitus

Increasing life expectancy and, as a consequence, a large number of comorbidities lead to a multitude of medications prescribed by physicians of different specialties. Patients with obesity and carbohydrate metabolism disorders, especially with type 2 diabetes mellitus (DM2), are at particular risk of polypragmasy, which is associated with the use of potentially nonrecommended medications. Prescribing errors can cause significant harm to the patient’s health and increase the risk of rehospitalization and healthcare costs. Identification of probably not recommended drugs in this category of patients will improve understanding of prevalence and risk factors of their use, develop strategies to prevent and limit the burden of taking inappropriate drugs and promote development of personalized and patient-oriented treatment options. Tools exist to assess potentially inappropriate therapy (PIT) in the elderly and new tools and criteria are often created. However, they are not specifically aimed at people with obesity and carbohydrate metabolism disorders. Thus, these criteria usually include only a few items related to DM2. Consequently, there is a clear need for a modern tool that can be used to address PIT specifically in older adults with obesity and carbohydrate metabolism disorders.

1. Federal’naja sluzhba gosudarstvennoj statistiki (Rosstat). Chislennost’ naselenija Rossijskoj Federacii po polu i vozrastu na 1 janvarja 2022 goda (statisticheskij bjulleten’). Moscow: 2022. (In Russ.).

2. World Health Organization. World Health Statistics 2021: Monitoring Health for the SDGs, Sustainable Development Goals. Bern, Switzerland: World Health Organization, The United Nations Statistics Division; 2021.

3. Australian Institute of Health and Welfare (AIHW). Chronic diseases and associated risk factors in Australia, 2006. Canberra: ACT; 2006.

4. Willadsen TG, Siersma V, Nicolaisdottir DR, et al. Guiding principles for the care of older adults with multimorbidity: An approach for clinicians. J Am Geriatr Soc. 2012;60(10):e041877. doi: https://doi.org/10.1111/j.1532-5415.2012.04188.x

5. Willadsen TG, Siersma V, Nicolaisdottir DR, et al. Symptom burden in multimorbidity: a population-based combined questionnaire and registry study from Denmark. BMJ Open. 2021;11(4):e041877. doi: https://doi.org/10.1136/bmjopen-2020-041877

6. Hölling H, Schlack R, Dippelhofer A, Kurth B-M. Personale, familiäre und soziale Schutzfaktoren und gesundheitsbezogene Lebensqualität chronisch kranker Kinder und Jugendlicher. Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz. 2008;51(6):606-620. doi: https://doi.org/10.1007/s00103-008-0537-2

7. Agarwal E, Miller M, Yaxley A, Isenring E. Malnutrition in the elderly: A narrative review. Maturitas. 2013;76(4):296-302. doi: https://doi.org/10.1016/j.maturitas.2013.07.013

8. Volkert D, Beck AM, Cederholm T, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019;38(1):10-47. doi: https://doi.org/10.1016/j.clnu.2018.05.024

9. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/ TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014;129(25S2):S139-140. doi: https://doi.org/10.1161/01.cir.0000437739.71477.ee

10. Gill LE, Bartels SJ, Batsis JA. Weight management in older adults. Curr Obes Rep. 2015;4(3):379-388. doi: https://doi.org/10.1007/s13679-015-0161-z

11. Sampson G. Weight loss and malnutrition in the elderly. Aust Fam Phys. 2009;38(7):507-510.

12. Belousov YuB, Leonova MV. Osobennosti primenenija lekarstv v geriatricheskoj praktike. Farmateka. 2008;(8):13-19. (In Russ.).

13. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. doi: https://doi.org/10.1080/03602530902722679

14. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi: https://doi.org/10.1016/S0140-6736(12)60240-2

15. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867. doi: https://doi.org/10.1001/jama.2008.892

16. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: https://doi.org/10.1186/s12877-017-0621-2

17. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989-995. doi: https://doi.org/10.1016/j.jclinepi.2012.02.018

18. Saraf AA, Petersen AW, Simmons SF, et al. Medications associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities. J Hosp Med. 2016;11(10):694-700. doi: https://doi.org/10.1002/jhm.2614

19. Partin B. Preventing medication errors: an IOM Report. Nurse Pract. 2006;31(12):8. doi: https://doi.org/10.1097/00006205-200612000-00002

20. Rossijskaja associacija gerontologov i geriatrov. Klinicheskie rekomendacii. Starcheskaja astenija. Moscow; 2021. 170 p. (In Russ.).

21. Alwhaibi M. Potentially inappropriate medications use among older adults with comorbid diabetes and hypertension in an ambulatory care setting. J Diabetes Res. 2022;2022:1-7. doi: https://doi.org/10.1155/2022/1591511

22. Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4):588-595. doi: https://doi.org/10.2337/dc14-0599

23. Redeker G, Bowles J. Tackling polypharmacy: A multisource decision support system. stud health technol inform. Stud Health Technol Inform. 2020;(270):688-692. doi: https://doi.org/10.3233/SHTI200248

24. Mkrtumyan AM, Biryukova EV. Osobennosti sakharnogo diabeta v pozhilom vozraste i printsipy terapii. Diabetes mellitus. 2005;8(4):14-21. (In Russ.). doi: https://doi.org/10.14341/2072-0351-5960

25. Leonova MV, Alimova EE. Clinical pharmacology in geriatrics. Clinical gerontology. 2018;(7-8). (In Russ.). doi: http://doi.org/10.26347/1607-2499201807-08032-039

26. Brill MJE, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277-304. doi: https://doi.org/10.2165/11599410-000000000-00000

27. Benedek I, Fiske 3d W, Griffen W, et al. Serum alpha 1‐acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol. 1983;16(6):751-754. doi: https://doi.org/10.1111/j.1365-2125.1983.tb02258.x

28. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care. 1995;18(7):986-991. doi: https://doi.org/10.2337/diacare.18.7.986

29. Gagnon-Auger M, du Souich P, Baillargeon J-P, et al. Dosedependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes. Diabetes Care. 2010;33(12):2502-2507. doi: https://doi.org/10.2337/dc10-1126

30. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine phakmacokinetics in obese and lean subjects. Ann Pharmacother. 1995;29(9):843-847. doi: https://doi.org/10.1177/106002809502900902

31. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 1998;55(4):563-584. doi: https://doi.org/10.2165/00003495-199855040-00007

32. Farrell GC, Teoh NC, Mccuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec. 2008;291(6):684-692. doi: https://doi.org/10.1002/ar.20715

33. Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and Co-morbidities. Obes Surg. 2003;13(4):622-624. doi: https://doi.org/10.1381/096089203322190853

34. Sharofova MU, Sagdieva SS, Yusufi SD. Diabetes mellitus: the modern state of the issue (part 1). Avicenna Bull. 2019;21(3):502-512. (In Russ.). doi: https://doi.org/10.25005/2074-0581-2019-21-3-502-512

35. Furmanova OV, Zak KP, Popova VV, Tronko MD. Lejkocitarnyj sostav i indeks sootnoshenija nejtrofilov i limfocitov v krovi u bol’nyh s vpervye vyjavlennym saharnym diabetom 2-go tipa v zavisimosti ot velichiny izbytochnoj massy tela/ozhirenija. Int J Endocrinol. 2021;16(7):526-533. (In Russ.). doi: https://doi.org/10.22141/2224-0721.16.7.2020.219006

36. International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation; 2017 [cited 09.08.2018]. Available from: http://www.diabetesatlas.org

37. Shestakova MV. Mozhno li izbezhat’ polipragmazii pri insulinzavisimom sakharnom diabete? Diabetes mellitus. 1999;2(1):28-30. (In Russ.). doi: https://doi.org/10.14341/2072-0351-5730

38. Gagnon M-E, Sirois C, Simard M, et al. Potentially inappropriate medications in older individuals with diabetes: A population-based study in Quebec, Canada. Prim Care Diabetes. 2020;14(5):529-537. doi: https://doi.org/10.1016/j.pcd.2020.03.003

39. Huang Y-T, Steptoe A, Wei L, Zaninotto P. Polypharmacy difference between older people with and without diabetes: Evidence from the English longitudinal study of ageing. Diabetes Res Clin Pract. 2021;(176):108842. doi: https://doi.org/10.1016/j.diabres.2021.108842

40. Gancgorn EV, Alekseev AN. Polipragmazija kak aktual’naja problema farmakoterapii bol’nyh saharnym diabetom tipa 2 v uslovijah stacionara. Molodoj uchenyj. 2014;4(63):343-346. (In Russ.). Доступно по: https://moluch.ru/archive/63/9980.

41. Koval’skaja GN, Mihalevich EN. Gosudarstvennyj reestr lekarstvennyh sredstv: mezhlekarstvennoe vzaimodejstvie. Voprosy obespechenija kachestva lekarstvennyh sredstv. 2019;3(25):59-65. (In Russ.).

42. Galstyan GR, Shestakova EA, Sklyanik IA. Obesity and type 2 diabetes: can we find a compromised treatment solution? Diabetes mellitus. 2017;20(4):270-278. (In Russ.). doi: https://doi.org/10.14341/DM8726

43. Saprina TV, Fajzulina NM. Diabetes type 2 diabetes in the elderly – solved and unsolved questions. Diabetes mellitus. 2016;19(4):322-330. (In Russ.). doi: https://doi.org/10.14341/DM7884

44. Sivitz WI, Phillips LS, Wexler DJ, et al. GRADE Research Group. Optimization of metformin in the GRADE Cohort: effect on glycemia and body weight. Diabetes Care. 2020;43(5):940-947. doi: https://doi.org/10.2337/dc19-1769

45. Salukhov VV, Ilyinskaya TA, Minakov AA. Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus. Endocrinology: News, Opinions, Training. 2022;11(1):39-52. (In Russ.). doi: https://doi.org/10.33029/2304-9529-2022-11-1-39-52

46. Krasnova NM, Sychev DA, Vengerovskii AI, Aleksandrova TN. Current methods of optimization of pharmacotherapy in elderly patients in multidisciplinary hospital. Clin Med. 2018;95(11):1042-1049. (In Russ.). doi: https://doi.org/10.18821/0023-2149-2017-95-11-1042-1049

47. Sychev DA, Danilina KS, Golovina ОV. The frequency of potentially inappropriate medication use according to the Beers’ criteria in elderly people at the therapy departments of a multidisciplinary hospital. Therapeutic Archive. 2015;87(1):27-30. (In Russ.). doi: https://doi.org/10.17116/terarkh201587127-30

48. Panova EA, Serov VA, Shutov AM, et al. Polypharmacy in elderly out patients. Ulyanovsk Medico-biological J. 2019;95(2):16-22. (In Russ.). doi: https://doi.org/10.34014/2227-1848-2019-2-16-22

49. Pavlichenko SN, Leonova MV, Upnickij AA. Osobennosti farmakoterapii u pozhilyh pacientov s mul’timorbidnost’ju: kriterii Birsa. Lechebnoe delo. 2017;(2):18-26. (In Russ.).

50. Abu-Naser D. Impact of clinical pharmacist interventions in prescribing errors in hospitalized diabetic patients with major polypharmacy. Hosp Pharm. 2021;56(4):392-399. doi: https://doi.org/10.1177/0018578720985428